Navigation Links
Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
Date:8/24/2007

PALO ALTO, Calif., Aug. 24 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, announced today that Mark A. Tarnopolsky, MD, PhD, FRCPC, professor at McMaster University in Hamilton, Ontario, Canada, presented a summary of findings demonstrating the positive effect of energy enhancing compounds for the potential treatment of neuromuscular diseases.

The findings were presented at the 10th International Congress on Amino Acids and Proteins (ICAAP) in Kallithea, Chalkidiki, Greece and is part of an ongoing collaborative program with Avicena to identify energy enhancing molecules as potential therapeutic agents for applications in neuromuscular diseases.

ABOUT AVICENA

Avicena Group, Inc. (OTC Bulletin Board: AVGO) is a Palo Alto, California based late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases. The company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). The company is currently analyzing data from its Phase IIb/III trial in ALS. Near term, Avicena intends to initiate a Phase III trial in Huntington's disease to accompany the ongoing NIH Phase III trial in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers.

SAFE HARBOR

This release contains forward-looking statements that reflect, among other things, management's current expectations, plans and strategies, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict. See "Risk Factors" under "Item 6. Management's Discussion and Analysis of Financial Condition and Results of Operation" from our Annual Report on Form 10-KSB for the year ended December 31, 2006, and other descriptions in the company's public filings with the Securities and Exchange Commission for a discussion of such risks, including the company's need for additional funds, the company's dependence on a limited number of therapeutic compounds, the stage of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, and the company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. Avicena does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.

Contact:

The Ruth Group (on behalf of Avicena Group)

Stephanie Carrington / Sara Ephraim / (investors)

(646) 536-7029 / 7002

scarrington@theruthgroup.com / sephraim@theruthgroup.com

Janine McCargo / Jason Rando (media)

(646) 536-7033 / 7025

jmccargo@theruthgroup.com / jrando@theruthgroup.com


'/>"/>
SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
2. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
3. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
6. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
7. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
8. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
9. Inspire Announces Presentations at Two European Scientific Conferences
10. HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
11. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 22, 2017 Research and Markets has announced ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... around 7.1% over the next decade to reach approximately $129.81 billion ... and forecasts for all the given segments on global as well ...
(Date:3/22/2017)... N.Y. , March 22, 2017 ... R-D™ Rapid Disinfector™ is the proven ultraviolet-C (UV-C) ... cause healthcare-associated infections (HAIs). Published ... Journal of Infection Control , the peer-reviewed study ... and experiences of Vancouver General Hospital and Rochester ...
(Date:3/22/2017)... YORK , March 22, 2017 ... (EP) market is growing rapidly due to the significant ... report published by Allied Market Research, the global electrophysiology ... expected to reach $8.271 billion by 2022, with a ... and is used to diagnose abnormal heartbeats or arrhythmia. ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... Pinnacle 1 Insurance, ... robust, ongoing community enrichment program, has announced their latest charity partner. The new ... for the critical needs of homeless families with children for thirty years. Compassionate ...
(Date:3/22/2017)... ... 22, 2017 , ... In recognition of Colon Cancer Awareness ... on cancer patients, cancer centers and advocacy groups, and MJH Studios™, a leading ... “No Ifs, Ands, or Butts,” that focuses on Colorectal Cancer detection, prevention and ...
(Date:3/22/2017)... ... March 22, 2017 , ... Drs. Jennifer Houck, Lauren ... base to accept new patients in need of skilled pediatric dentistry in ... Dental Care offers pediatric patients routine treatments, including cavities, sealants and fluoride applications, in ...
(Date:3/22/2017)... Park Ridge, NJ (PRWEB) , ... March 22, ... ... financial planning firm that serves communities throughout north Jersey and the New York ... Bergen County to provide regional support for homeless families. , At present, more ...
(Date:3/22/2017)... ... , ... Schneider Insurance and Financial, a southern Montana firm providing asset protection ... is launching a charity event aimed at raising local support for Zoo Montana. , ... and is home to a broad variety of animals from all over the world. ...
Breaking Medicine News(10 mins):